Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMT and Harmine (RE01) Dose-response in Healthy Subjects
NCT05829603Phase 1Completed
- Sponsor
- Reconnect Labs
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of DMT and harmine in cocaine use disorder (CUD) and stimulant use disorder (SUD) (2 arms), sponsored by Reconnect Labs. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve and 11 more. Started May 2023; status: completed.
02
Drugs
DMTharmine
03
Conditions
cocaine use disorder (CUD)stimulant use disorder (SUD)
Beyond the preview
Go deeper on NCT05829603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829603.